On July 10, 2009, Mentor Capital announced it had acquired a significant interest in and was a new public market proxy for Quantum Immunologics, Inc., a private company in FDA breast cancer trials. Oncothyreon (NASDAQ:ONTY - News), with significant lung cancer involvement, followed in CI Index performance with a 71% gain in its stock. Dendreon (NASDAQ:DNDN - News), with $2.7 Billion market capitalization, is the largest company in the Cancer Immunotherapy Index, and experienced a 1,000% share price gain during the Spring of 2009.

In cancer immunotherapy, instead of chemotherapy, surgeries and radiation, the body's own immune system is triggered to attack cancer cells. Patients report only flu-like symptoms as their now activated natural defenses attempt to eradicate or stabilize the targeted cancers. The USA market addressed by the Cancer Immunotherapy Index companies is estimated at $45 Billion.

The current combined market cap of the index component companies is $3.4 Billion. In addition to Mentor Capital, Oncothyreon and Dendreon, the CI Index features ImmunoCellular Theraputics (IMUC.OB), Antigenics (NASDAQ:AGEN - News), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX - News), Northwest Biotherapeutics (NWBO.OB), CEL - SCI Corp. (AMEX:CVM - News) and Generex Biotechnology (NASDAQ:GNBT - News) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express.

The CI Index was developed in consultation with Mike Havrilla, PhD, co-founder and Managing Editor of BioMed Reports. Dr. Havrilla actively manages 23 indexes. The Cancer Immunotherapy Index is primarily an immunotherapy subset of his Cancer Diagnostic & Therapeutic (Dx/Tx) Micro-Cap Index. Weekly detail updates of the Cancer Immunotherapy Index may be reviewed at Mentor Capital's website.

 Disclosure: Long IMUC.ob, MNTR.pk